These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 589601

  • 21. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
    Laliberté J, Marquez VE, Momparler RL.
    Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
    Parise RA, Egorin MJ, Eiseman JL, Joseph E, Covey JM, Beumer JH.
    Rapid Commun Mass Spectrom; 2007; 21(13):1991-7. PubMed ID: 17526067
    [Abstract] [Full Text] [Related]

  • 25. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B, Capizzi RL, Kute TE, Morgan T, Dimling J.
    Cancer Res; 1989 Jun 15; 49(12):3259-66. PubMed ID: 2720678
    [Abstract] [Full Text] [Related]

  • 26. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.
    Momparler RL, Eliopoulos N, Bovenzi V, Létourneau S, Greenbaum M, Cournoyer D.
    Cancer Gene Ther; 1996 Jun 15; 3(5):331-8. PubMed ID: 8894252
    [Abstract] [Full Text] [Related]

  • 27. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
    Xiang TX, Niemi R, Bummer P, Anderson BD.
    J Pharm Sci; 2003 Oct 15; 92(10):2027-39. PubMed ID: 14502542
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
    White JC, Hines LH.
    Cancer Res; 1987 Apr 01; 47(7):1820-4. PubMed ID: 3028615
    [Abstract] [Full Text] [Related]

  • 30. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM, Otter GM, Schmid FA.
    Cancer Res; 1993 Feb 01; 53(3):587-91. PubMed ID: 8425192
    [Abstract] [Full Text] [Related]

  • 31. Physiologic disposition of cytosine arabinoside and its derivatives in man.
    Kreis W, Woodcock TM, Meyers MB, Carlevarini LA, Krakoff IH.
    Cancer Treat Rep; 1977 Jul 01; 61(4):723-6. PubMed ID: 195729
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Distribution of [3H]cytosine arabinoside and its products in mice, dogs, and monkeys and effect of tetrahydrouridine.
    Dareer SM, Mulligan LT, White V, Tillery K, Mellett LB, Hill DL.
    Cancer Treat Rep; 1977 Jul 01; 61(3):395-407. PubMed ID: 406044
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
    Beumer JH, Eiseman JL, Parise RA, Florian JA, Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2008 Aug 01; 62(3):457-64. PubMed ID: 18008070
    [Abstract] [Full Text] [Related]

  • 36. Identification of cytidine deaminase as inhibitor of granulocyte-macrophage colony formation.
    Bøyum A, Løvhaug D, Seeberg E, Nordlie EM.
    Exp Hematol; 1994 Feb 01; 22(2):208-14. PubMed ID: 7507861
    [Abstract] [Full Text] [Related]

  • 37. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI, Bernacki RJ, Hui SW, Rustum Y, West CR.
    Cancer Res; 1990 Jul 15; 50(14):4401-6. PubMed ID: 2364392
    [Abstract] [Full Text] [Related]

  • 38. Modulation of the effect of 1-beta-D-arabinofuranosylcytosine based on changes of cytidine deaminase activity in HL60 cells.
    Mejer JN, Mortensen BT, Christensen IJ.
    Med Oncol Tumor Pharmacother; 1990 Jul 15; 7(1):25-9. PubMed ID: 2338846
    [Abstract] [Full Text] [Related]

  • 39. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH, Taub JW.
    J Natl Cancer Inst; 2005 Feb 02; 97(3):226-31. PubMed ID: 15687366
    [Abstract] [Full Text] [Related]

  • 40. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V, Xu YZ, Estey E.
    Clin Cancer Res; 1998 Jul 02; 4(7):1719-26. PubMed ID: 9676847
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.